Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > hmm...that's odd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(112)
•••
Comment by MBT123on Nov 24, 2020 2:23am
177 Views
Post# 31958606

RE:RE:hmm...that's odd

RE:RE:hmm...that's oddSure your already aware BTI has never/ever released anything news deals tables at a conference.. etc..that has increased share holder value..Every single news  release(written by ol JD) has no timelines ever! With convoluted details on money....But it's always so such good news!! They(Dr.R&JD) spew there comparisons to Denali on here while our SP actually went down when ol JD was pumping Denali...What's the deal Dr.R?? You ran one company to pennies..If we're so close to them where is the outside interest from the states???????  They obviously don't see any comparison to us and Denali...So whatever you and JD spewing here doesn't fly in the "actual" pharma community..Our SP shows reality..but they will say lots going on blah blah blah 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities